Processa Pharmaceuticals (PCSA) Earnings Date & Reports

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PCSA is expected to report earnings to rise 25.00% to -10 cents per share on March 28

Processa Pharmaceuticals PCSA Stock Earnings Reports

Q4'23

Est.

$-0.10

Q3'23

Beat

by $0.02

Q2'23

Beat

by $0.05

Q1'23

Beat

by $0.05

Q4'22

Missed

by $0.49

The last earnings report on November 08 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 2.42M shares outstanding, the current market capitalization sits at 1.58M.

View a ticker or compare two or three

Compare

PCSA